FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
-------------	------	-------

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APP	OMB APPROVAL								
OMB Number:	3235-0287								
Estimated average burden									
hours per response	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person*     Rhodes Jason P				2. Issuer Name <b>and</b> Ticker or Trading Symbol Generation Bio Co. [GBIO]								neck all ap	plicable) ctor	Ü	son(s) to Iss 10% Ov	ner			
(Last) (First) (Middle) C/O GENERATION BIO CO., 301 BINNEY ST					3. Date of Earliest Transaction (Month/Day/Year) 06/09/2021								Off bel	cer (give w)	title	Other (s below)	pecify		
(Street) CAMBR (City)			02142 (Zip)		4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Lir	e) X For For	ridual or Joint/Group Filing (Check Applicable  Form filed by One Reporting Person  Form filed by More than One Reporting  Person				
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																		
1. Title of Security (Instr. 3)  2. Transac Date (Month/Date)				Execution Date,		3. Transac Code (II							Form (D) o	m: Direct or Indirect Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)				
						Code	v	Amount	(A) or (D)	Price	Trans	action(s) 3 and 4)			(iiisti. 4)				
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Da if any (Month/Day/		ransaction ode (Instr.		of E		6. Date Exercisab Expiration Date (Month/Day/Year)		of Securities		ies g Security	8. Price Derivati Security (Instr. 5	deriv Secu Bene Own Folic Repo	wing orted saction(s)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
				c	ode	v	(A)		Date Exercisabl		expiration Pate	Title	Amount or Number of Shares						
Stock Option (right to buy)	\$26.59	06/09/2021			A		15,000		(1)	0	6/08/2031	Common Stock	15,000	\$0		15,000	D <sup>(2)</sup>		

## **Explanation of Responses:**

- 1. This option was granted on June 9, 2021. The shares underlying the option will fully vest on the earlier of: June 9, 2022 and the date of Generation Bio's 2022 annual meeting of stockholders.
- 2. This option was granted to the Reporting Person, a director of the Issuer. The proceeds of any sale of shares of common stock issued to the Reporting Person upon exercise of this option will be transferred to Atlas Venture Life Science Advisors, LLC and as such, the Reporting Person disclaims ownership of such securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any.

/s/ Ommer Chohan, Attorneyin-Fact

06/11/2021

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.